← Back to Search

Procedure

tDCS + Cognitive Training for Alzheimer's Disease

N/A

Waitlist Available

Research Sponsored by Baycrest

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial will test whether administering transcranial direct current stimulation (tDCS) at 4.0 mA, rather than the conventional 2mA, will produce more significant improvements in people with Alzheimer's Disease.

Who is the study for?

This trial is for individuals with mild to moderate Alzheimer's Disease who score between 18 and 25 on the MoCA cognitive test and can perform a memory task. It excludes those with stroke or brain injury history, metal implants/shunts in their body, or significant heart disease, alcoholism, or drug use.Check my eligibility

What is being tested?

The study tests if transcranial direct current stimulation (tDCS) at a higher intensity of 4mA combined with cognitive training can be more effective than the conventional 2mA for improving symptoms in Alzheimer's patients.See study design

What are the potential side effects?

Potential side effects of tDCS may include discomfort at the electrode site, itching, tingling during application, headache, fatigue, nausea. However these are generally mild and temporary.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

N-Back

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: 4mA StimulationExperimental Treatment1 Intervention

Group II: 2mA StimulationActive Control1 Intervention

Group III: SHAMPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

BrightFocus FoundationOTHER

4 Previous Clinical Trials

386 Total Patients Enrolled

BaycrestLead Sponsor

43 Previous Clinical Trials

5,925 Total Patients Enrolled

Media Library

tDCS (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05508841 — N/A

Alzheimer's Disease Research Study Groups: 4mA Stimulation, 2mA Stimulation, SHAM

Alzheimer's Disease Clinical Trial 2023: tDCS Highlights & Side Effects. Trial Name: NCT05508841 — N/A

tDCS (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05508841 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for this research endeavor?

"According to clinicaltrials.gov, the original posting for this trial was on September 1st 2022 and has since been updated as of August 19th 2022 - indicating that recruitment is no longer active. However, there are still 548 other medical research studies actively seeking participants at this time."

Answered by AI

Are individuals of a youthful age able to join this experiment?

"The upper age limit of this trial is 90 years old, while the lower age threshold set by researchers is 50 years."

Answered by AI

Who can be approved to partake in this experiment?

"The qualifications for this study include a diagnosis of Alzheimer's disease and an age between 50 and 90. There is space in the trial for approximately 42 people."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation

Tyler Roncero 2022. "Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05508841.

All > Tdcs